Last reviewed · How we verify
EG-007
EG-007 is a selective inhibitor of the sodium- potassium pump.
EG-007 is a selective inhibitor of the sodium- potassium pump. Used for Symptomatic heart failure, Reducing the risk of cardiovascular death and hospitalization in heart failure.
At a glance
| Generic name | EG-007 |
|---|---|
| Sponsor | Evergreen Therapeutics, Inc. |
| Drug class | sodium-potassium pump inhibitor |
| Target | sodium-potassium pump |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the sodium-potassium pump, EG-007 aims to reduce the workload on the heart, thereby alleviating symptoms of heart failure. This is achieved by reducing the heart's energy expenditure and improving its pumping efficiency.
Approved indications
- Symptomatic heart failure
- Reducing the risk of cardiovascular death and hospitalization in heart failure
Common side effects
- Hypokalemia
- Fatigue
- Dizziness
Key clinical trials
- Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem (PHASE2)
- Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EG-007 CI brief — competitive landscape report
- EG-007 updates RSS · CI watch RSS
- Evergreen Therapeutics, Inc. portfolio CI